We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Read MoreHide Full Article
Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.
We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.
The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.
The Zacks Earnings ESP, Explained
The Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.
The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.
Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.
Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.
Should You Consider Iovance Biotherapeutics?
Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Iovance Biotherapeutics (IOVA - Free Report) earns a #3 (Hold) right now and its Most Accurate Estimate sits at -$0.33 a share, just 19 days from its upcoming earnings release on August 13, 2024.
Iovance Biotherapeutics' Earnings ESP sits at +10.12%, which, as explained above, is calculated by taking the percentage difference between the -$0.33 Most Accurate Estimate and the Zacks Consensus Estimate of -$0.37. IOVA is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
IOVA is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is Illumina (ILMN - Free Report) .
Slated to report earnings on August 6, 2024, Illumina holds a #2 (Buy) ranking on the Zacks Rank, and it's Most Accurate Estimate is $0.89 a share 12 days from its next quarterly update.
Illumina's Earnings ESP figure currently stands at +279.87% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.23.
Because both stocks hold a positive Earnings ESP, IOVA and ILMN could potentially post earnings beats in their next reports.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.
We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.
The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.
The Zacks Earnings ESP, Explained
The Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.
The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.
Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.
Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.
Should You Consider Iovance Biotherapeutics?
Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Iovance Biotherapeutics (IOVA - Free Report) earns a #3 (Hold) right now and its Most Accurate Estimate sits at -$0.33 a share, just 19 days from its upcoming earnings release on August 13, 2024.
Iovance Biotherapeutics' Earnings ESP sits at +10.12%, which, as explained above, is calculated by taking the percentage difference between the -$0.33 Most Accurate Estimate and the Zacks Consensus Estimate of -$0.37. IOVA is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
IOVA is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is Illumina (ILMN - Free Report) .
Slated to report earnings on August 6, 2024, Illumina holds a #2 (Buy) ranking on the Zacks Rank, and it's Most Accurate Estimate is $0.89 a share 12 days from its next quarterly update.
Illumina's Earnings ESP figure currently stands at +279.87% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.23.
Because both stocks hold a positive Earnings ESP, IOVA and ILMN could potentially post earnings beats in their next reports.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>